


Toward improving pregnancy outcomes by study of human placental development using *in vitro* models

Bala Rao

People
**Chrissy Teigen and Kim Kardashian Ate Their
Placentas, But Is It Safe? A Doctor Weighs In**





Trophoblast


“Trophos” = Nourishment

Trophoblast




Placenta

**Nourishment for the
developing fetus**



Embryo (Day 5)



Laboratory Culture




Human Embryonic Stem Cell:
Can be grown Indefinitely

Scientists Bypass Need for Embryo to Get Stem Cells


By GINA KOLATA

Published: November 21, 2007



Blastocyst apposition

Endometrial surface
(pinopode)




Blastocyst

550 μm

6 days


Blastocyst apposition

- First step of implantation is apposition
- Upon attachment of endometrium lining, trophoblast proliferates into a double layer
- Outer layer cells fuse forming **syncytiotrophoblast (STB)**
 - one multinucleated cell
- Inner layer, **cytotrophoblasts (CTB)**
 - stem cell compartment
 - able to form all trophoblast subtypes




Blastocyst invasion

- STB invades into endometrium
 - interstitial invasion
- CTBs continuously replenishes STB as blastocyst invades
- Prelacunar stage



Lacunar stage


- CTBs proliferate and differentiate upon contact of maternal tissue
- Large STB mass increase at embryonic pole compared to anti-implantation pole
- Large vacuoles of water appear within STB
 - quickly expand into lacunae
 - separated pillars of STB are trabeculae



d8-9 p.c.


Primary villi formation


- CTBs proliferate and expand into trabeculae from chorionic plate (CP)
 - primary villi structure
 - surrounded STB
 - become **villous cytotrophoblasts (vCTB)**
 - lose CDX2, gain P63 expression
 - further villi sprouting occurs
- Lacunae expand into intervillous space (IVS)
- Extraembryonic mesoderm (EM) surrounded by CTBs at CP



Secondary villi formation


- EM expands past chorionic plate into villi
 - secondary villi structure
- vCTBs proliferate past STB forming the cytotrophoblastic shell (CS)
 - villi in contact of CS are anchoring villi
 - CTBs of the anchoring villi are column cytotrophoblasts (cCTBs)







Tertiary villi formation


- Appearance of fetal capillaries
 - tertiary villi structure
 - nutrient-gas exchange
- cCTBs differentiate into **extravillous cytotrophoblasts (EVTs)**
 - migrate into endometrium
 - adapt maternal vessels and cells
- EVT made up of interstitial, endovascular, endoglandular cells
- Decidua (D) formation within endometrium








- iCTBs differentiate and replace endothelial lining of arteries
- Increase uteroplacental perfusion



- Too little invasion
- Preeclampsia




Too much invasion

Motivation for studying trophoblasts (TBs)

- Large role in placental disorders
 - Preeclampsia (low invasion)
 - Abnormally invasive placenta (high invasion)
 - Intrauterine growth restriction

Motivation for studying TBs

- High maternal death rates
 - USA has rising maternal death rate
 - 16% Preeclampsia
 - 17% Hemorrhage
- 70% of conceptions are lost
 - 30% implantation failure
 - 30% early pregnancy loss
 - 10% miscarriage




Motivation for studying TBs

- High maternal death rates
 - USA has rising maternal death rate
 - 16% Preeclampsia
 - 17% Hemorrhage
- 70% of conceptions are lost
 - 30% implantation failure
 - 30% early pregnancy loss
 - 10% miscarriage

Early development poorly understood

- unreliable animal models
- human embryo research restraints
- lack of early trophoblast models
- “Least understood organ” - NIH




Questions?


Human TB model

- Limited research
 - human samples scarce
 - ethical restrictions
- Choriocarcinoma-derived TBs
 - similar TB functions
 - syncytialization and invasion
 - vast differences from primary samples
 - transcriptome differences
 - lack of multipotency
- Past isolated 1st trimester placenta samples underwent rapid differentiation


Healthy Trophoblasts



Trophoblastic choriocarcinoma



Embryo (Day 5)




→ Laboratory Culture



Human Embryonic Stem Cell:
Can be grown Indefinitely

Can we model trophoblast from pluripotent stem cells?


Early reports




Xu et al. Nat Biotechnol. 2002 Dec;20(12):1261-4

Perspectives from mouse

- Mouse Trophoblast Stem Cell (TSC)
 - Self-renewal
 - Differentiates into all trophoblast cell types
 - No human equivalent until 2018




- Mouse ESCs “do not form trophectoderm”




GFP+ ESCs do not form TE when injected in 4-8 cell stage embryos

Previous reports





Previous reports




Our previous work

- Inhibition of Activin/Nodal (SMAD2/3) is required for trophoblast differentiation
- Cells express CTB markers, e.g. CDX2, ELF5, and EOMES
- **Hypomethylation of cells**
- **Low expression levels of HLA class I molecules**





Our previous work

- Activin/Nodal switch determines terminal fate of TB subtype formation




- Able to form both STB and EVTs
 - STB key markers KRT7 and Syncytin
 - STB multinucleated cells
 - EVTs express HLA-G
 - EVTs mononuclear mesenchymal cells




Differentiation of TB from hESCs

- Characterization is a challenge
 - poor availability of markers (eg. CDX2 in mesoderm, KRT7 in extraembryonic mesoderm)
 - limited comparison to in vivo tissue (<4 weeks)
 - Lee et al. (2016) guidelines
 - Hypomethylation at ELF5 promoter region
 - Express KRT7, GATA3, TFAP2C
 - Expression of C19MC miRNAs
 - Expression of HLA-G not HLA class I molecules




Human trophoblast stem cells

- Past TBs isolated 1st term placenta samples underwent rapid differentiation
- **Two models systems** maintained from primary samples




New models

- Past TBs isolated 1st term placenta samples underwent rapid differentiation
- Two models systems maintained from primary samples
 - organoid
 - 3D villi model
 - **physiological differences (CTB on periphery)**
 - **transcriptome differences**



Human trophoblast stem cells

- Past TBs isolated 1st term placenta samples underwent rapid differentiation
- Two models systems maintained from primary samples
 - human trophoblast stem cell (hTSC) *Okae
 - forms STB and EVT
 - similar transcriptome
 - representative of vCTBs




Human trophoblast stem cells

- Past TBs isolated 1st term placenta samples underwent rapid differentiation
- Two models systems maintained from primary samples
 - human trophoblast stem cell (hTSC) *Okae
 - **lack early trophectoderm markers (CDX2)**
 - **Limited genetic diversity of lines**
 - **Outcome of pregnancy unknown**

Can human pluripotent stem cells overcome these limitations?

Potentially...



Questions?

Acknowledgments




Adam Mischler



National Institutes
of Health


Overview of hESC-derived model

- All hESC-derived TB models limited
 - Culture medium composed of:
 - Feeder cell conditioned medium (FCM)
 - Knockout serum replacement (KOSR)
 - Bovine serum albumin
- FCM and KOSR contain serum factors and lipid species
 - difficult characterization
 - confound mechanistic analysis
- Switch to defined culture medium (e.g. TeSR-E8)
 - Neural formation (Activin/Nodal inhibition)
 - Mesoderm/Extraembryonic mesoderm (BMP4 treatment)
 - **Defined medium missing lipid species**
 - **sphingosine-1-phosphate (S1P)**
 - **lysophosphatidic acid (LPA)**




Serum factors linked to YAP signaling


- YAP essential for TB formation in human and mouse early development
- YAP activation downstream of lipid factors
 - Spingosine-1-phosphate (S1P)
 - Lysophosphatidic acid(LPA)
- LPA caused cell death upon treatment
- S1P allow TB differentiation
- Utilize S1P to develop a serum-free defined medium for differentiation of TBs from hESCs



A chemically defined medium with S1P




B CTB markers after 6 day treatment




S1P treatment of hESCs leads to CTB-like cell

- Expressed CTB markers P63 and GATA3
- Pan marker KRT7 expression




6 Day Treatment CTB




C

EVT markers after 12 day treatment




D

STB markers after 14 day treatment




E

EVT markers (without S1P)




F

STB markers (without S1P)




Formation of TB acts through receptor mediated S1P signaling

- S1P can initiate cellular response through:
 - receptor mediated signaling
 - S1P Receptors 1-5
 - internalization and ceramide pathway
- D-erythro-dihydrospingosine-1-phosphate (dhS1P)
 - does not internalize
 - receptor mediated only




Formation of TB acts through receptor mediated S1P signaling

- CTB markers with dhS1P treatment
 - CDX2, GATA3, TEAD4, P63
- Able to form EVT and STB
 - marker expression
 - morphology




Agonists of S1P₁₋₃ all form hESC-derived TBs

- S1P can act through receptors 1-5
 - TBs contain S1PR₁₋₃
 - specific agonist initiate TB differentiation
 - more defined medium
- S1PR₁ agonist – CYM5442
- S1PR₂ agonist – CYM5520
- S1PR₃ agonist – CYM5541




IHC from 1st
trimester placenta




Agonists of S1P₁₋₃ all form hESC-derived TBs

- All agonists differentiate to all CTB-like cells
 - CYM5541 (S1P₃) gives strongest CDX2 expression
 - P63 expression nuclear/cytoplasmic




Agonists of S1P₁₋₃ all form hESC-derived TBs

- All agonists differentiate to all TBs
 - CYM5520 (S1P₂) preference towards STB
 - CYM5442 (S1P₁) preference towards EVT
- CYM5541 (S1P₃) most consistent results in EVT and STB differentiation and high CTB marker expression
- **Cannot maintain CTBs from 6 day treatment**
 - differentiation in TSCM from Okae et al.
 - further optimization is required
 - develop media for hTSCs





Reduced treatment duration of hESCs retains stem cell potential

- Initial 6-day treatment suboptimal
 - P63 expression cytoplasmic
 - heterogeneous CDX2 expression
 - loss of stem cell compartment
- shorter treatment required**
 - homogeneous CDX2 expression
 - nuclear localization P63



3 Day Treatment CTB




Establishment and maintenance of CDX2⁺ hTSCs

- Following 3-day treatment passaged into:

- CYM5541 (S1P₃ agonist)
- FGF10 (growth factor)
- *CHIR99021 (GSK-3β inhibitor)
- *A83-01 (Activin/Nodal inhibitor)



* within trophoblast stem cell medium (TSCM) developed by Okae et al



- **Retained for >25 passages (3+ months)**


Establishment and maintenance of CDX2⁺ hTSCs

- Cells express key CTB markers
 - retain CDX2 expression (trophectoderm marker)
 - low P63 expression (villous CTB)
 - express key CTB markers
- TM-4 (trophectoderm media, 4 components)




Primary TS^{CT} cells from Okae lab


- Compare hTSCs to primary cells
- Okae et al. established hTSCs from primary placenta and blastocyst samples (TS^{CT})
 - grown in TSCM
 - loss of CDX2 expression
 - retains P63 expression
 - villous CTB-like cell
 - able to differentiate to EVT and STB



DIC Primary TS^{CT} cells in TSCM




Primary TS^{CT} cells in TSCM





Formation of hTSCs^{P63} from hESCs and hTSCs^{CDX2} in TSCM

- Stable hTSCs^{P63} from hTSC^{CDX2} or 3-day treated hESCs
 - stable after 3-4 passages
 - low differentiation from hTSC^{CDX2}
 - high differentiation from 3-day treated hESCs
 - maintain for 25+ passages (3+ months)




DIC hTSCs^{P63} in TSCM




Formation of hTSCs^{P63} from hESCs and hTSCs^{CDX2} in TSCM

- hTSCs^{P63}
 - loss of CDX2
 - high P63 expression
 - morphologically similar to TS^{CT} cells


DIC hTSCs^{P63} in TSCM



DIC Primary TS^{CT} cells in TSCM




Proliferative H9 hTSC^{P63} in TSCM



Directed differentiation of hTSCs^{P63} into STB and EVT



STB

- express Syncytin and hCG
- large multinucleated
- secrete hCG




EVTs


- mononuclear
- mesenchymal
- express HLA-G




H9 STB from hTSC^{P63}




H9 EVT from hTSC^{P63}





Transcriptome comparison



- Placenta-derived TS #1
- Placenta-derived TS #2
- hESC 3 Day Treatment (H1)
- hESC (H1)
- hPSC-TS^{CDX2} (H1)
- hPSC-TS (H1)
- hESC 3 Day Treatment (H9)
- hESC (H9)
- hPSC-TS^{CDX2} (H9)
- hPSC-TS (H9)




Transcriptome comparison




Other published studies since 2019

- Shahbazi et al. (2020; doi:10.1038/s41467-020-17764-7)
 - Replicated our method to generate a knockout trophoblast stem cell from hESCs
- Dong et al. (2020; doi:10.7554/elife.52504) and Cinkornpumin et al. (2020; 10.1016/j.stemcr.2020.06.003)
 - Showed CDX2⁻ trophoblast stem cells can be derived from pluripotent stem cells
 - Naïve vs primed embryonic stem cells
 - CDX2⁺ cells have not been maintained

Why CDX2 may be important








A potential approach for a reproducible, ethically sound, and physiologically accurate model for human embryo implantation

Summary

- Two distinct stem cell populations of the placental lineage can be derived from human pluripotent stem cells
- iPSC models of trophoblast can **accelerate research into placental pathology**
- iPSC models can enable **research into early embryo development**



Questions?